Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intercell's acquisition of Iomai approved

This article was originally published in Scrip

Executive Summary

Intercell's acquisition of Iomai was approved by the US-based vaccine specialist's shareholders in a meeting held on August 1st. Intercell will now acquire Iomai for $6.60 per share of the company's common stock, representing a total payment of $189 million. The acquisition, which is expected to close within the next few days, was approved by 99.97% of the votes cast, representing over 71% of the outstanding shares entitled to vote at the meeting.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts